EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Pharmacokinetic properties of insulin GZR4 after subcutaneous administration in the thigh, abdomen, or upper arm in healthy participants

Long Liu, Junmin Dong, Yuanxu Tong, Pu Li, Xiaoyun Liu, Xiaoqiang Cheng, Yingjuan Zhang, Chunpu Lei, Fang Cheng, Jing Zhao, Wei Zhao, Wei Chen und 1 weitere

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70461 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Long Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Insulin. Die Arbeit nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This trial aimed to evaluate the impact of different subcutaneous injection regions on the pharmacokinetics and safety of the once‐weekly basal insulin GZR4 in healthy Chinese participants. Materials and Methods This randomized, open‐label, three‐period crossover trial enrolled 24 healthy participants. Each participant received a single subcutaneous injection of GZR4 (3 nmol/kg) in the thigh, abdomen, and deltoid region of the upper arm (upper arm), respectively. This was followed by a four‐week observation period, with an additional one‐week interval between each injection. Blood samples were collected regularly to assess the pharmacokinetic (PK) characteristics of GZR4. The primary endpoint was the area under the concentration‐time curve from 0 to 672 h after a single dose (AUC 0–672h ) across injection regions. Secondary endpoints included additional PK parameters, safety, and immunogenicity.

Results

The GZR4 exposure (AUC 0–672h ) was comparable across injections in the thigh, abdomen, and upper arm. The geometric mean AUC 0–672h ratio (90% CI) for abdomen/upper arm was 104.8% (96.5%, 113.9%), for abdomen/thigh was 102.6% (94.5%, 111.4%), for thigh/upper arm was 102.2% (94.1%, 110.9%); all within the predefined equivalence range of 80.0%–125.0%. A total of 22 participants (91.7%) experienced 51 treatment‐emergent adverse events (TEAEs), and all TEAEs were mild or moderate in severity. No hypoglycaemic events, serious adverse events, or deaths were reported.

Conclusions

In healthy Chinese participants, subcutaneous injection of GZR4 in the thigh, abdomen, or upper arm displayed comparable drug exposure, with no clinically meaningful differences observed among the injection regions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoglycemic AgentsInsulinHumansMaleAdultInjections, SubcutaneousFemaleThighCross-Over StudiesArmAbdomenArea Under CurveYoung AdultHealthy VolunteersMiddle Aged

Stichwörter der Autor:innen

GZR4diabetesonce‐weeklypharmacokinetics

Substanzen

Hypoglycemic AgentsInsulin

Autor:innen und Institutionen

  • Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Gan & Lee Pharmaceuticals, Beijing, China.
  • Gan & Lee Pharmaceuticals Shandong Co., Ltd., Shandong, China.

Zitieren

APA

Liu, L., Dong, J., Tong, Y., Li, P., Liu, X., Cheng, X., Zhang, Y., Lei, C., Cheng, F., Zhao, J., Zhao, W., Chen, W., & Hao, X. (2026). Pharmacokinetic properties of insulin GZR4 after subcutaneous administration in the thigh, abdomen, or upper arm in healthy participants. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70461

Vancouver

Liu L, Dong J, Tong Y, Li P, Liu X, Cheng X, et al. Pharmacokinetic properties of insulin GZR4 after subcutaneous administration in the thigh, abdomen, or upper arm in healthy participants. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70461

BibTeX
@article{Liu2026,
  author = {Liu, Long and Dong, Junmin and Tong, Yuanxu and Li, Pu and Liu, Xiaoyun and Cheng, Xiaoqiang and Zhang, Yingjuan and Lei, Chunpu and Cheng, Fang and Zhao, Jing and Zhao, Wei and Chen, Wei and Hao, Xiaohua},
  title = {Pharmacokinetic properties of insulin GZR4 after subcutaneous administration in the thigh, abdomen, or upper arm in healthy participants},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70461}
}
Kostenlos starten →